EGFR and lung adenocarcinoma: Peled et al. also reported that osimertinib displayed potent intracranial activity against EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases in both previously treated and treatment-naive groups, regardless of T790M status [229].